Literature DB >> 21287896

Rapid HIV testing and obstetrical characteristics of women with unknown HIV serostatus at time of labor and delivery.

Chi Dola1, Thuc Tran, Can Duong, Chris Federico, Nathaniel DeNicola, Robert Maupin.   

Abstract

OBJECTIVE: To describe the obstetrical characteristics of women without prenatal care and/or undocumented human immunodeficiency virus (HIV) serostatus who presented for delivery and to assess the usefulness of rapid HIV screening in these women.
MATERIALS AND METHODS: The study design was a retrospective analysis. Demographics, labor, delivery characteristics, and pregnancy outcomes of women without prenatal care and/or unknown HIV serostatus were reviewed.
RESULTS: Three hundred fifty parturients met the inclusion criteria: 15.2% presented at complete cervical dilation, 48.6% with cervical dilation of at least 5 cm, and 43.1% with ruptured membranes. Twenty-two percent of parturients delivered within 1 hour of admission, 47.6% delivered within 4 hours of admission, and 5.5% delivered prior to arrival to the hospital. With the lengthy admission process and procurement of zidovudine from the pharmacy requiring at least 1 hour at best, 27.5% would not have the benefit of intrapartum zidovudine treatment. Single Use Diagnostic System HIV-1 rapid test was reactive and confirmed in 7 women (2.5%).
CONCLUSION: Rapid HIV screening is a useful tool for guiding immediate obstetrical management and coordinated care for the neonate. In some circumstances, the full benefit of rapid HIV detection will not be realized due to advanced labor, ruptured members, or delivery prior to arrival.

Entities:  

Mesh:

Year:  2010        PMID: 21287896     DOI: 10.1016/s0027-9684(15)30770-7

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  1 in total

1.  Prevalence and predictors of unknown HIV status among women delivering in Mulago National Referral Hospital, Kampala, Uganda.

Authors:  Emily C Namara-Lugolobi; Gertrude Nakigozi; Zikulah Namukwaya; Dan K Kaye; Edith Nakku-Joloba
Journal:  Afr Health Sci       Date:  2017-12       Impact factor: 0.927

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.